Johnson Matthey cuts price of catalyst business sale to Honeywell

Johnson Matthey has reduced the agreed enterprise value for the sale of its Catalyst Technologies division to Honeywell to £1.325bn (cash- and debt-free) from £1.8bn and extended the long-stop date to 21 July (with a possible further extension to 21 August), aiming to complete by end-August. The firm now expects to return about £1.0bn to shareholders (down from £1.4bn) via a £200m buyback and an £800m special dividend with share consolidation, citing deferred licensing projects and weaker catalyst profitability in a challenging market; JM says it remains on track to deliver 2026 guidance, targeting underlying operating profit growth at the higher end of mid-single digits and materially higher positive free cash flow.

Analysis

Market structure: Honeywell (HON) is the clear near-term beneficiary — a £1.325bn EV buy at a haircut reduces overpay risk versus the original £1.8bn and should be modestly EPS/accretive within 12 months if integration and licensing ramp as planned. Johnson Matthey shareholders and catalyst-focused peers face pricing pressure: the write-down signals weaker demand and deferred licensing in refining/petrochemicals, likely reducing near-term PGM (platinum/palladium) catalyst volumes by a low-double-digit percent vs. prior forecasts. Cross-asset: expect modest tightening in HON credit spreads (buy-side support), widening in JMAT FX/GBP sensitivity on lower cash return, and mild downside for PGM prices if catalyst volumes disappoint further.

Risk assessment: Key tail risks are (1) antitrust block or extended remedy that reopens price negotiations before 21 Aug, (2) activist/legal challenge over reduced shareholder return, and (3) deeper-than-stated demand decline that forces further write-downs. Immediate (days) risk is headline-driven volatility; short-term (weeks–months) hinges on antitrust timeline to 21 Jul/21 Aug; long-term (quarters) depends on structural demand for emissions/licensing technology. Hidden dependency: JMAT’s FY26 guidance partially assumes sale cash — failure to complete would force capital-allocation pivot and could trigger covenant/credit stress.

Trade implications: Tactical pair: establish a small size long HON (1–2% portfolio) vs. short JMAT (1%–1.5%) into the Aug close — target 8–15% relative return over 3–9 months, stop-loss 8% absolute. Options: buy a 9–12 month HON call spread (approx. 5%–10% OTM) to cap premium outlay and buy 6-month puts on JMAT ~10% OTM as a cheap downside hedge; if implied vol jumps on delays, convert to collars. Rotate 2–4% from specialty-chemicals exposure into industrial automation/defense (HON, XLI) to reduce cyclicality.

Contrarian angles: Consensus treats the haircut as pure negative; missed is the structural benefit to JMAT of de-risking a cyclical catalysts unit — if sale completes at £1.325bn and capital return executes, JMAT could re-rate on simplified cash-flow profile within 6–12 months, creating a mean-reversion long opportunity. Historical parallels: negotiated deal-price reductions often precede a short-term sell-off then stabilization post-close (examples: divestments 2017–2019). Unintended consequence: the share consolidation + special dividend can compress free float and increase volatility—use option hedges around the ex-date.

Key Decisions for Investors

• Establish a 1.5% portfolio long position in Honeywell (HON) within the next 2–6 weeks, target 10% upside within 6–12 months, place a protective stop at -8% and reduce if antitrust extends beyond 21 Aug 2026.
• Initiate a 1%–1.5% short or buy 6-month puts (~10% OTM) on Johnson Matthey (JMAT) aiming for 10%–20% downside into the Aug close if the sale proceeds, cut if JMAT announces alternative buyers or licensing recoveries within 60 days.
• Execute a relative-value pair: long HON (1.5%) / short JMAT (1%) to target ~8% absolute and 12% relative return over 3–9 months; rebalance if antitrust approval arrives earlier than 21 Jul or is denied.
• Buy a 9–12 month HON call spread (5%–10% OTM) sized to 0.5% portfolio risk to capture accretion while limiting premium; concurrently buy 6-month JMAT puts (~10% OTM) as downside protection against reopen of negotiations.
• Shift 2% portfolio weight from specialty catalysts/small-cap chemical names into industrials/automation (e.g., XLI/HON) to lower exposure to deferred licensing risk; reassess after sale completion and ex-dividend/share consolidation within 30 days.